thyroid cancer
Conditions
Interventions
None listed
Sponsors
Japan Association of Endocrine Surgery
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Persons who meet all of the following selection criteria (1) through (4) (1) Those who meet any of the following 1) Those diagnosed with differentiated thyroid cancer that is not curable by radical resection 2)) Those diagnosed with anaplastic thyroid cancer 3) Those diagnosed with medullary thyroid cancer that cannot be radically resected. (2) Patients who have undergone or are scheduled to undergo Oncomine Dx to determine if serpercatinib is indicated. (3) 12 years of age or older at the time of obtaining written consent (4) Persons who can give written consent to participate in this study after receiving sufficient explanation.
Exclusion criteria
Exclusion criteria: (1) Persons deemed unsuitable as subjects by the principal investigator or physician in charge
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To elucidate the frequency of genetic mutations in each pathological type of advanced thyroid cancer in Japan. | — |
Secondary
| Measure | Time frame |
|---|---|
| (1) To determine the association between genetic mutations in differentiated thyroid cancer and response to radioiodine therapy. (2) To determine the type and frequency of gene mutations in patients previously treated with multi-kinase inhibitors. | — |
Countries
Japan
Contacts
Public ContactAmane Hara
Data Center for Oncomine DxTT Accumulation Study on Thyroid Cancer Clinical Research Support Center, Shinshu University Hospital
Outcome results
None listed